Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma
- Evidence of clinical activity observed in Cohort 8, including stringent complete remission in two patients from Cohort 8
- HDP-101 continues to demonstrate a favorable safety profile with no dose-limiting toxicities observed in Cohort 8
- R&D Webinar to be hosted on 11 November 2025 at 05:00 pm CET (08:00 am PST)
Ladenburg, Germany, 6 November 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that HDP-101 (INN: pamlectabart tismanitin), the Company’s lead ATAC candidate for the treatment of relapsed or refractory multiple myeloma, shows further clinical activity in Cohort 8 at a dose level of 140 µg/kg. These findings are highlighted by observed stringent complete remissions in two patients from Cohort 8.
